IHE
iShares U.S. Pharmaceutical ETF
NYSEArcaUSDETF / FUND
DELAYED
Last price
107.83
▲ 2.11 (2.00%)
MARKET · —
Price
Open
105.72
Prev close
105.72
Day high
107.38
Day low
105.51
Volume
299.30K
Market cap
—
P/E (TTM)
28.15
52W range
69.02 – 108.66
Trailing performance
Returnvs SPY
1W
+4.02%
+5.4%
1M
+4.71%
+1.0%
3M
+18.08%
+15.0%
6M
+18.85%
+7.8%
YTD
+25.89%
+13.6%
1Y
+52.14%
+32.1%
3Y
+68.34%
-5.8%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Top holdings
| Symbol | Name | Weight | |
|---|---|---|---|
| JNJ | Johnson & Johnson | 22.09% | |
| LLY | Eli Lilly and Co | 20.78% | |
| BMY | Bristol-Myers Squibb Co | 4.83% | |
| VTRS | Viatris Inc | 4.55% | |
| MRK | Merck & Co Inc | 4.49% | |
| RPRX | Royalty Pharma PLC Class A | 4.40% | |
| PFE | Pfizer Inc | 4.02% | |
| ZTS | Zoetis Inc Class A | 3.91% | |
| JAZZ | Jazz Pharmaceuticals PLC | 3.53% | |
| ELAN | Elanco Animal Health Inc | 2.93% |
Sector exposure
Healthcare
100.00%
Fund profile
Fund familyiShares
CategoryHealth
Legal typeExchange Traded Fund
Expense ratio0.37%
Turnover29.0%
Total net assets$89.67M
Fundamentals
Market cap—
Enterprise value—
Revenue (TTM)—
Gross profit—
EBITDA—
Net income—
EPS (TTM)—
Free cash flow—
Total cash—
Total debt—
Book value / share—
Shares outstanding—
Float—
Short % of float—
Dividend yield—
Beta (5Y)—
Valuation & profitability ratios
Trailing P/E28.15
Forward P/E—
PEG ratio—
Price / sales—
Price / book—
EV / revenue—
EV / EBITDA—
Gross margin—
Operating margin—
Profit margin—
Return on equity—
Return on assets—
Debt / equity—
Current ratio—
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Analyst targets & ownership
Mean target—
High target—
Low target—
Implied upside—
Analyst count—
Consensus—
Strong buy / Buy— / —
Hold—
Sell / Strong sell— / —
Held by insiders—
Held by institutions—
Institutions holding—
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
104.44
+3.25% from price
SMA 20
103.40
+3.27% from price
SMA 50
100.35
+6.42% from price
SMA 100
94.54
+14.06% from price
SMA 200
90.09
+18.53% from price
EMA 12
104.52
+3.16% from price
EMA 26
102.88
+4.81% from price
EMA 50
100.34
+7.47% from price
RSI (14)
64.2
Neutral
MACD (12,26,9)
1.64
Hist 0.26
ATR (14)
1.93
1.81% of price
Realised vol 30D
18.3%
Annualised
Bollinger upper
106.99
20, 2σ
Bollinger lower
99.82
20, 2σ
50 / 200 cross
Golden
100.35 vs 90.09
Trend bias
Above 200
+18.53%
Risk profile
Beta vs SPY
0.37
Less volatile than market
Correlation to SPY
0.26
Largely independent
Realised vol 30D
18.3%
Annualised
Market vol 1Y
12.9%
SPY, annualised
Max drawdown 1Y
-8.8%
Peak to trough
Max drawdown 5Y
-17.4%
Peak to trough
ATR 14
1.93
1.81% of price
Beta (reported)
—
5Y monthly, from filing
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Options analytics
Put / call volume
—
—
Put / call open interest
4.20
Positioning, not flow
Max pain
100.00
-6.4% from spot
ATM implied vol
34.4%
Nearest strike to spot
Skew (10% OTM)
+21.3%
Puts bid over calls
Call volume
0
Contracts, this expiry
Put volume
1
Contracts, this expiry
Heaviest call OI
99.00
3 contracts
Heaviest put OI
100.00
11 contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Headlines
Moderna's 177% Surge Powers a Broad Biotech Rally
etf.com · 2d ago
Healthcare ETFs Are Looking Up: Here's Why
Zacks · 3d ago
Will Generic Drug Tariffs Impact Pharma ETFs?
Zacks · 23d ago
ETFs to Buy Post JNJ's Q2 Earnings Beat & Bullish 2026 Outlook
Zacks · 30d ago
Should You Invest in the iShares U.S. Pharmaceuticals ETF (IHE)?
Zacks · 38d ago
Healthcare ETFs to Buy as JNJ Beats the Market With a 25% YTD Surge
Zacks · 39d ago
Inside the GLP-1 Boom: ETF Picks for the Obesity Drug Market
Zacks · 73d ago
Middle East Erupts Again: Buy these Healthcare ETFs Before the Next Strike
Zacks · 74d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.